Drug intelligence / Profile preview

68Ga-3BP-3940

Development stage: Unknown
Lead developer: 3B Pharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

68Ga-3BP-3940 is a gallium-68-labeled peptide radiopharmaceutical developed by 3B Pharmaceuticals for the PET/CT imaging of solid tumors. The agent consists of 3BP-3940, a highly potent and selective peptide inhibitor of Fibroblast Activation Protein (FAP), conjugated to a DOTA chelator. FAP is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of various solid malignancies. 68Ga-3BP-3940 is designed for prolonged tumor retention and serves as a companion diagnostic to identify patients suitable for FAP-targeted radioligand therapy, such as 177Lu-FO-004.

Other names: [68Ga]Ga-3BP-3940Ga-68-3BP-3940Ga68-3BP-3940Ga 68-3BP-3940

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on 68Ga-3BP-3940.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-3BP-3940.

Explore the full profile